スライド 1

Incidence of Grade 2+ neuropathy
(%)
C
HR=1.731 ( 0.982-3.049)
P=0.056
Data Cutoff 6 Apr 2012
100
90
Goshajinkigan
N=74
80
70
60
50
40
30
Placebo
N=68
20
10
HR=1.908 ( 1.181-3.083)
P=0.007
Data Cutoff 21 Dec 2012
(%)
Incidence of Grade 2+ neuropathy
A
100
90
Goshajinkigan
N=89
80
70
60
50
40
30
Placebo
N=93
20
10
0
0
0
1
2
3
4
5
6
7
8
0
9 10 11 12
1
2
3
4
Time (month)
90
80
70
60
50
40
Placebo
N=68
30
20
10
0
0
1
2
3
4
5
6
7
7
8
9 10 11 12
8
Time (month)
9 10 11 12
HR=1.771 ( 1.066-2.941)
P=0.025
Data Cutoff 21 Dec 2012
(%)
Incidence of Grade 2+ neuropathy
Incidence of Grade 2+ neuropathy
D
Goshajinkigan
N=74
100
6
Time (month)
HR=2.022 ( 1.083-3.776)
P=0.025
Data Cutoff 6 Apr 2012
(%)
B
5
Goshajinkigan
N=89
100
90
80
70
60
50
40
Placebo
N=93
30
20
10
0
0
1
2
3
4
5
6
7
8
Time (month)
9 10 11 12
(%)
Incidence of Grade 1+ neuropathy
A
100
90
80
70
Goshajinkigan N=89
60
50
40
30
HR=1.450 (1.029-2.042)
P=0. 051
Placebo
N=93
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (course)
B
Incidence of Grade 2+ neuropathy
(%)
100
90
80
HR=1.774 (1.104-2.853)
P=0.018
70
Goshajinkigan N=89
60
50
Placebo
N=93
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (course)
C
Incidence of Grade 3+ neuropathy
(%)
100
90
HR=1.437 (0.640-3.228)
P=0.
80
70
Goshajinkigan N=89
60
50
Placebo
40
30
20
10
0
0 1 2 3 4 5 6 7 8 9 10 11 12
Time (course)
N=93

Download Report